|Bid||2.356 x 0|
|Ask||2.446 x 0|
|Day's Range||2.356 - 2.356|
|52 Week Range||1.910 - 4.180|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
It can be hard finding stocks that can offer significant returns, but there are some intriguing reasons Celldex Therapeutcis, Helmerich & Payne, and SodaStream might be heading much higher.
The Motley Fool co-founder has enjoyed much success in the market, but not even the best investors have a flawless record.
It was a punishing year for this biotech's shareholders, but several wise steps could spell success in the new year and beyond.
These two biotech stocks have taken very different paths this year. Let's see how they stack up against each other right now.
Whether you’re an income investor seeking steadily rising dividends or hunting for explosive growth potential, these healthcare stocks are on sale.
Legendary investors such as Leon Cooperman and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that big brokerage houses don’t publish. Small cap stocks -especially when they are screened well- can generate substantial outperformance versus a boring index fund. That’s why we analyze the […]
Celldex Therapeutics (CLDX) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.